Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...

London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...

GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned ...

A trial has shown that belantamab mafodotin can reduce the risk of death by 42% in patients with relapsed or refractory ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

智通财经APP获悉，葛兰素史克 (GSK.US)报告称，一项研究表明，其药物 belantamab mafodotin 能够将多发性骨髓瘤患者在首次复发时或复发后的死亡风险降低 42%。

GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in ...

GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain ...

OGeez! is leaving a big ticket, year-end gift for the cannabis community: A new Sugar Free gummy.  The gummy, which ...

Wire 3, a leading provider of high-speed fiber-optic internet, today announced the closing of a $115 million credit facility. The facility, led by Woodforest National Bank, CIBC, and JPMorgan, with ...

GSK (GSK) announced “statistically significant and clinically meaningful” overall survival results from a planned interim analysis of the ...

Belantamab Mafodotin shows significant OS benefit, reducing the risk of death by 42% in multiple myeloma at or after first ...